by admin | Mar 17, 2025 | News
Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy Mont-Saint-Guibert, Belgium (March 17, 2025) – EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising...
by admin | Jan 8, 2025 | News
Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletionAt 28 days after a single dose of ESO-T01, no cancer cells were detected in the bone marrowESO-T01 is being developed in...
by admin | Dec 11, 2024 | News
ESO-T01 is the first in vivoBCMA CAR-T candidate to reach the clinical stage Early clinical data are expected in second half of 2025 Mont-Saint-Guibert, Belgium (December 11, 2024) – EsoBiotec SA, a biotechnology company empowering cells in vivo to fight cancer, today...
